Ryan Hanley

he said what's happened.

And he, he said, I'm actually not talking about that anymore.

He goes, I, I'm actually starting to think that these large private companies, it's actually a way better way of running a business.

Like if you don't need that public capital, like make that a last resort because you, you,

you now have the ability to kind of sidestep all of this regulatory compliance committee responsibility kind of stuff.

And now you're just your customers, your employees, and your investors.

And that's who you're responsible for.

And it's much easier to manage.

And do you see this move almost back to more private businesses away from IPOs?

You see that as a future trend or a trend that continues?

I also think that, I'm with you, I believe in private companies for sure, but

I think philosophically, I would love to see more companies able to IPO for the reason, the latter reason that you just suggested, which is, you know, a personal anecdote is I invested in a company.

They're actually on a Toronto Stock Exchange, a Canadian company that is moving into the U.S.

that does licensed psilocybin therapy for veterans specifically.

So PTSD, you know, very popular.

you know, very targeted clinical, you know, this isn't recreational at all.

This is targeted therapy.

But I mean, this is like 80 plus percent response rates.

I mean, these are, these are changing, you know, particularly men seem to respond to this a little more than women, but women just as much if they had the PTSD.

But I mean, changing lives, I mean, drastically reducing suicide rates, drastically reducing, you know, things like domestic abuse and domestic assaults in the homes because these guys aren't coming home, like just filled with rage from these situations they've been put in.